ClinicalTrials.gg
RecruitingNCT05889741Updated Nov 18, 2026

Combining Stellate Ganglion Block With Prolonged Exposure for PTSD

A Phase 2 interventional study of Ropivacaine injection and Normal saline in Stress Disorders, Post-Traumatic, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by The University of Texas Health Science Center at San Antonio · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.
Updated Nov 18, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio — 8 open to participants now, 8 under way, none of them phase 3. Stress Disorders, Post-Traumatic · The University of Texas Health Science Center at San Antonio.

Planned enrollment
8th of 25
140 · median 49
Started
2024
the only one that year
Phase 2
Only one
of the 27
Registered
19th of 27
by date

Among the 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio, this one is the 8th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 2, and was the 19th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

8 of the 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of military service members or retirees with PTSD. The main questions it aims to answer are: (1) Does the addition of an SGB improve treatment outcomes associated with Massed PE and (2) Do differences in psychophysiological arousal during the exposure portion of treatment help explain treatment outcomes for PTSD. Participants will receive ten 90-minute session of Massed PE. Between the first and second Massed PE sessions, half of the participants will receive a SGB, and half will receive a sham SGB.

Read the detailed description

Massed PE will be conducted by master-level or doctoral-level therapists. Participants will meet with their providers for individual, 90-minute sessions. They will then be asked to complete out-of-session treatment assignments throughout the rest of the day. Between the individual therapy session and out-of-session treatment assignments, participants will engage in approximately four to six hours of treatment per day, Monday through Friday, for two weeks. Each participant will also be offered three booster sessions at 1-, 3-, and 7-weeks posttreatment.

The stellate ganglion block injection or the sham SGB will be administered between the first and second massed PE session by qualified medical personnel as per standard operating procedure for the placement of a stellate ganglion block. A research nurse will be in attendance during the procedure and for an hour recovery period following the block administration.

Assessments will be administered at pretreatment, during treatment, at posttreatment, and at 1-, 3-, and 6-months following the completion of PE. The primary outcome assessment will be 1-month following the completion of PE. Following this assessment, participants randomized to the sham SGB arm of the study will be offered an SGB with ropivacaine.

03

Conditions studied

  • Stress Disorders, Post-Traumatic

Keywords

  • SGB
  • Military
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Active duty and retired military service members ages 18-65 years
  2. PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale
  3. Able to speak and read English (due to standardization of outcome measures)
  4. Defense Enrollment Eligibility Reporting System (DEERS)-eligible to receive care at a military treatment facility (MTF) where the stellate ganglion block will be placed.

Exclusion criteria

Exclusion Criteria:

  1. Current suicidal ideation severe enough to warrant immediate attention (as determined by the Depressive Symptoms Index - Suicidality Subscale and the Self-Injurious Thoughts and Behaviors Interview short form) and corroborated by a clinical risk assessment by a credentialed provider.
  2. Current manic episode or psychotic symptoms requiring immediate stabilization or hospitalization (as determined by clinical judgment)
  3. Symptoms of moderate to severe substance use (to include alcohol) warranting immediate intervention based on clinical judgment.
  4. Other psychiatric disorders severe enough to warrant designation as the primary disorder as determined by clinician judgment
  5. Pregnancy or breastfeeding
  6. Current anticoagulant use
  7. History of bleeding disorder
  8. Infection or mass at injection site
  9. Myocardial infarction within 6 months of procedure
  10. Pathologic bradycardia or irregularities of heart rate or rhythm
  11. Symptomatic hypotension
  12. Phrenic or laryngeal nerve palsy
  13. History of glaucoma
  14. Uncontrolled seizure disorder
  15. History of allergy to local anesthetics
  16. Current use of Class III antiarrhythmics
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Stellate Ganglion Block

    One time administration of a stellate ganglion block

    Drug: Ropivacaine injection

  • Placebo comparator
    Sham SGB

    One time administration

    Drug: Normal saline

Interventions

  • DrugRopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion

    Also known as: Naropin

  • DrugNormal saline

    6.5cc of Normal Saline one time into the stellate ganglion.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Clinician-Administered PTSD Scale-DSM 5 (CAPS-5)

    A 30-item structured interview used to assess change symptoms of PTSD. Questions target the onset and duration of symptoms, subjective distress, impact on social and occupational functioning. Total severity scores range from 0 to 80 with higher score indicative of greater PTSD severity. The measure can also be used to confirm the presence of a PTSD diagnosis.

    Time frame: Baseline and at 1-month, 3-month, and 6-month follow-up assessments

  2. Change from baseline in Posttraumatic Stress Disorder Checklist -DSM 5 (PCL-5)

    A 20-item self-report measure that assesses the presence and change in severity of PTSD symptoms using the Diagnostic and Statistical Manual of mental disorders (DSM-5). Total severity scores range from 0 to 80 with higher score indictive of greater PTSD severity.

    Time frame: Baseline and at 1-month, 3-month, and 6-month follow-up assessments

Secondary outcomes

  1. Patient Health Questionnaire-9 items (PHQ-9)

    A 9-item self-report measure that assesses the presence and change in severity of depressive symptoms. Total scores range from 0 to 27 with higher scores reflective of greater severity.

    Time frame: Baseline and at 1-month, 3-month, and 6-month follow-up assessments

  2. General Anxiety Disorder Screener - 7 Items (GAD-7)

    A 9-item self-report measure that assesses the presence and change in severity of general anxiety symptoms. Total scores range from 0 to 21 with higher scores reflective of greater severity.

    Time frame: Baseline and at 1-month, 3-month, and 6-month follow-up assessments

  3. Posttraumatic Cognitions Inventory (PTCI)

    A 36-item self-report measure that assesses change in self-blame, negative cognitions about self, and negative cognitions about the world following trauma exposure. Total scores range from 33 to 231 with higher scores reflective of more problematic cognitions.

    Time frame: Baseline and at 1-month, 3-month, and 6-month follow-up assessments

  4. Psychophysiological arousal - Galvanic Skin Response

    Change in Psychophysiological data collected from a smart watch measuring galvanic skin response

    Time frame: Two weeks

  5. Psychophysiological arousal - Skin Temperature

    Change in Psychophysiological data collected from a smart watch measuring skin temperature

    Time frame: Two weeks

  6. Psychophysiological arousal - Heart Rate

    Change in Psychophysiological data collected from a smart watch measuring heart rate

    Time frame: Two weeks

  7. Psychophysiological arousal - Interbeat Interval

    Change in Psychophysiological data collected from a smart watch measuring interbeat interval

    Time frame: Two weeks

  8. Psychophysiological arousal - Three-Dimensional Accelerometer Movement

    Change in Psychophysiological data collected from a smart watch measuring three-dimensional accelerometer movement

    Time frame: Two weeks

  9. Psychophysiological arousal - Electrodermal Activity

    Change in Psychophysiological data collected from a smart watch measuring electrodermal activity

    Time frame: Two weeks

  10. Psychophysiological arousal - Photoplethysmography

    Change in Psychophysiological data collected from a smart watch measuring photoplethysmography

    Time frame: Two weeks

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Foa EB, McLean CP, Zang Y, Rosenfield D, Yadin E, Yarvis JS, Mintz J, Young-McCaughan S, Borah EV, Dondanville KA, Fina BA, Hall-Clark BN, Lichner T, Litz BT, Roache J, Wright EC, Peterson AL; STRONG STAR Consortium. Effect of Prolonged Exposure Therapy Delivered Over 2 Weeks vs 8 Weeks vs Present-Centered Therapy on PTSD Symptom Severity in Military Personnel: A Randomized Clinical Trial. JAMA. 2018 Jan 23;319(4):354-364. doi: 10.1001/jama.2017.21242. PubMed 29362795 ↗
  • Hanling SR, Hickey A, Lesnik I, Hackworth RJ, Stedje-Larsen E, Drastal CA, McLay RN. Stellate Ganglion Block for the Treatment of Posttraumatic Stress Disorder: A Randomized, Double-Blind, Controlled Trial. Reg Anesth Pain Med. 2016 Jul-Aug;41(4):494-500. doi: 10.1097/AAP.0000000000000402. PubMed 27187898 ↗
  • Lipov EG, Joshi JR, Lipov S, Sanders SE, Siroko MK. Cervical sympathetic blockade in a patient with post-traumatic stress disorder: a case report. Ann Clin Psychiatry. 2008 Oct-Dec;20(4):227-8. doi: 10.1080/10401230802435518. No abstract available. PubMed 19034755 ↗
  • Lynch JH, Mulvaney SW, Kim EH, de Leeuw JB, Schroeder MJ, Kane SF. Effect of Stellate Ganglion Block on Specific Symptom Clusters for Treatment of Post-Traumatic Stress Disorder. Mil Med. 2016 Sep;181(9):1135-41. doi: 10.7205/MILMED-D-15-00518. PubMed 27612365 ↗
  • Mulvaney SW, Lynch JH, Hickey MJ, Rahman-Rawlins T, Schroeder M, Kane S, Lipov E. Stellate ganglion block used to treat symptoms associated with combat-related post-traumatic stress disorder: a case series of 166 patients. Mil Med. 2014 Oct;179(10):1133-40. doi: 10.7205/MILMED-D-14-00151. PubMed 25269132 ↗
  • Odosso RJ, Petta L. The Efficacy of the Stellate Ganglion Block as a Treatment Modality for Posttraumatic Stress Disorder Among Active Duty Combat Veterans: A Pilot Program Evaluation. Mil Med. 2021 Jul 1;186(7-8):e796-e803. doi: 10.1093/milmed/usaa246. PubMed 33242072 ↗
  • Peterson AL, Blount TH, Foa EB, Brown LA, McLean CP, Mintz J, Schobitz RP, DeBeer BR, Mignogna J, Fina BA, Evans WR, Synett S, Hall-Clark BN, Rentz TO, Schrader C, Yarvis JS, Dondanville KA, Hansen H, Jacoby VM, Lara-Ruiz J, Straud CL, Hale WJ, Shah D, Koch LM, Gerwell KM, Young-McCaughan S, Litz BT, Meyer EC, Blankenship AE, Williamson DE, Roache JD, Javors MA, Sharrieff AM, Niles BL, Keane TM; Consortium to Alleviate PTSD. Massed vs Intensive Outpatient Prolonged Exposure for Combat-Related Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023 Jan 3;6(1):e2249422. doi: 10.1001/jamanetworkopen.2022.49422. PubMed 36602803 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Mar 2028, 49 months after the start.

Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's planned 49 months is close to that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Mar 2027 → Mar 2028 and completion Aug 2027 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2023
First posted
Jun 5, 2023
StartActual
Feb 26, 2024
Primary completionEst.
Mar 31, 2028was Mar 2027
CompletionEst.
Aug 31, 2028was Aug 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Brook Army Medical Center (BAMC) · Fort Sam Houston, United States
Nov 18, 2026
Primary completion
Mar 31, 2027→Mar 31, 2028
Nov 18, 2026
Study completion
Aug 31, 2027→Aug 31, 2028
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    1 site added
    Show site
    • Brook Army Medical Center (BAMC) · Fort Sam Houston, United States
    Primary completion Mar 31, 2027→Mar 31, 2028
    Study completion Aug 31, 2027→Aug 31, 2028
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05889741
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
Feb 26, 2024
Primary completion
Mar 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Amanda Flores
Contact
floresa13@uthscsa.edu
210-562-6726
Alan Peterson, PhD
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion